Carrick Therapeutics is delighted to have been successful at this year’s Biotech and Money Awards Gala in London. The Awards recognised success and achievement over the past year in the biotech sector in the UK and Ireland.
Carrick won the award for the “Private Finance Raise of the Year (>£25M)”, which was open to privately owned life science companies and their lead investors.
The nominees were:
Atlas Genetics – £28.3m, Series D, Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners and Wondfo Biotech
Bicycle Therapeutics – £40m, Series B, Vertex Ventures, Cambridge Innovation Capital, Longwood Fund. Novartis VG, SR-One, SVLS and Atlas Venture
Carrick Therapeutics – £74m, Series A, ARCH Venture Partners and Woodford Investment Management, Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital
Cell Medica – £60m, Series C, Touchstone Innovations, Invesco Perpetual and Woodford Investment Management
F2G – £46.5m, Series E, Sectoral Asset Management, Novo A/S, Aisling Capital, Advent Life Sciences, Novartis VF, Sunstone, Merifin Capital
Kymab – £78m, Series C,ORI Healthcare Fund
Oxford Nanopore – £100m, Venture Financing, GT Healthcare Healthcare Partners, Woodford Investment Management and IP Group Plc
Carrick was launched last October with $95m of initial funding. Its lead investors are ARCH Venture Partners and Woodford Investment Management, with participation from Lightstone Ventures, GV (Google Ventures), Cambridge Enterprise, Cambridge Innovation Capital and Evotec.
Welcoming the award, Dr Elaine Sullivan, CEO of Carrick Therapeutics, said:
“It is a great honour for Carrick Therapeutics to have received this award from hundreds of key figures in the life science sector and investment community. We have made great progress in our first year, with big ambitions for the future.”
Biotech and Money, organisers of the Biotech and Money Assembly and Awards Dinner, are an influential community of senior life science decision makers. They are a catalyst for dialogue, debate and deal making to help lead growth in healthcare.